The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Bayer; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Simon Paul Watkins
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology; United Health Group
 
Darrin Despain
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Chris Alan Karlovich
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Andrew Simmons
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Consulting or Advisory Role - Redwood Bioscience
 
Anthony A. Golsorkhi
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Simon Chowdhury
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi
Research Funding - Johnson & Johnson; Sanofi